Search research articles
Contact Us
Filters
Showing results (21-30 of 190) with videos related to
Page
of 19
Sort By:
JAMA Oncology
|
July 24, 2015
Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No Harm
Charles D Blanke, Erik K Fromme
Seminars in Oncology
|
October 5, 2015
Progress and Infrastructure for Improved Patient Outcomes of the National Cancer Institute Network Groups
C D Blanke, Walter J Curran
Clinical Advances in Hematology & Oncology : H&O
|
September 17, 2005
Gastrointestinal stromal tumors and the evolution of targeted therapy
Rachel E Sanborn, Charles D Blanke
Journal of Medical Economics
|
November 12, 2010
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors
Charles D Blanke, Daniel M Huse
Seminars in Oncology
|
December 22, 1999
Topoisomerase I inhibitors in the treatment of colorectal cancer
M L Rothenberg, C D Blanke
Current Opinion in Oncology
|
March 1, 1995
Combined modality therapy in non-small cell lung cancer
C D Blanke, D H Johnson
Current Treatment Options in Oncology
|
October 13, 2006
Gastrointestinal stromal tumors: imatinib and beyond
Ian D Schnadig, Charles D Blanke
Medical & Biological Engineering & Computing
|
April 15, 2003
Spanning set defines variability in locomotive patterns
M J Kurz, N Stergiou, D Blanke
Oncology (Williston Park, N.Y.)
|
November 7, 1999
The role of UFT in combined-modality therapy
C D Blanke, M Teng, H Choy
Archives of Physical Medicine and Rehabilitation
|
June 1, 1982
Flexibility training: ballistic, static or proprioceptive neuromuscular facilitation?
S P Sady, M Wortman, D Blanke
Page
of 19
Search research articles
Search
Showing results (21-30 of 190) with videos related to
Sort By:
Page
of 19
JAMA Oncology
|
July 24, 2015
Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No Harm
Charles D Blanke, Erik K Fromme
Seminars in Oncology
|
October 5, 2015
Progress and Infrastructure for Improved Patient Outcomes of the National Cancer Institute Network Groups
C D Blanke, Walter J Curran
Clinical Advances in Hematology & Oncology : H&O
|
September 17, 2005
Gastrointestinal stromal tumors and the evolution of targeted therapy
Rachel E Sanborn, Charles D Blanke
Journal of Medical Economics
|
November 12, 2010
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors
Charles D Blanke, Daniel M Huse
Seminars in Oncology
|
December 22, 1999
Topoisomerase I inhibitors in the treatment of colorectal cancer
M L Rothenberg, C D Blanke
Current Opinion in Oncology
|
March 1, 1995
Combined modality therapy in non-small cell lung cancer
C D Blanke, D H Johnson
Current Treatment Options in Oncology
|
October 13, 2006
Gastrointestinal stromal tumors: imatinib and beyond
Ian D Schnadig, Charles D Blanke
Medical & Biological Engineering & Computing
|
April 15, 2003
Spanning set defines variability in locomotive patterns
M J Kurz, N Stergiou, D Blanke
Oncology (Williston Park, N.Y.)
|
November 7, 1999
The role of UFT in combined-modality therapy
C D Blanke, M Teng, H Choy
Archives of Physical Medicine and Rehabilitation
|
June 1, 1982
Flexibility training: ballistic, static or proprioceptive neuromuscular facilitation?
S P Sady, M Wortman, D Blanke
Page
of 19